who medicines strategy - libdoc.who.int - World Health Organization

REFERENCES | 1471Annual report 2000, Essential Drugs and Medicines Policy. Geneva, World Health Organization,2001 (WHO/EDM/2001.4); Annual report 2001, Essential Drugs and Medicines Policy: Extending theevidence base. Geneva, World Health Organization, 2002 (WHO/EDM/2002.1); Annual report 2002,Essential Drugs and Medicines Policy: Supporting countries to close the access gap. Geneva, WorldHealth Organization, 2003 (WHO/EDM/2003.1).2Essential drugs in brief. Geneva, World Health Organization. Journal issued three times per year.3World Health Assembly Resolutions Revised drug strategy (A53/10 and A54/17) and WHO medicinesstrategy (A55/12 and A56/16).4How to develop and implement a national drug policy. WHO Policy Perspectives on Medicines, No.6.Geneva, World Health Organization, 2003 (WHO/EDM/2002.5).5Questionnaire on country pharmaceutical situations. Geneva, World Health Organization, 2003 (EDM/DAP).6Globalization, TRIPS and access to pharmaceuticals. WHO Policy Perspectives on Medicines, No. 3.Geneva, World Health Organization, 2001 (WHO/EDM/2001.2).7Annual report 2002, Essential Drugs and Medicines Policy: Supporting countries to close the access gap.Geneva, World Health Organization, 2003 (WHO/EDM/2003.1).8Implications of the Doha Declaration on the TRIPS Agreement and Public Health. Geneva, World HealthOrganization, 2002. Health Economics and Drugs, EDM Series No. 12 (WHO/EDM/PAR/2002.3).9Annual report 2002. Op. cit.10Troullier P et al. Lancet, 2002, 359:2188-94; Pécoul B et al. Fatal imbalance. The crisis in researchand development for drugs for neglected diseases. Geneva, Médecins Sans Frontièrès. 2001.(www.accessmed-msf.org); Morel CM. Parasitology Today, 2001.11Introducing the gender perspective in national essential drugs programmes. Geneva, World HealthOrganization, 2001 (EDM/DAP/2001.1).12http://www.who.int/gender/documents/fact/en/13World development report 2003. New York, United Nations Development Programme, 2003.14Ethical criteria for medicinal drug promotion. Geneva, World Health Organization, 1988(http://www.who.int/medicines/library/dap/ethical-criteria/ethicalen.shtml).15Davidoff F et al. Sponsorship, authorship and accountability. Lancet, 2001, 325:854-856 (publishedsimultaneously in 12 other medical journals).16http://www.transparency.org/17http://www.corisweb.org/18WHO traditional medicine strategy 2002-2005. Geneva, World Health Organization, 2002 (WHO/EDM/TRM/2002.1).19World Health Assembly Resolution 56.31. Traditional medicine.20Legal status of traditional medicine and complementary/alternative medicine. Geneva, World HealthOrganization, 2001 (WHO/EDM/TRM/2001).21Global comparative pharmaceutical expenditures with related reference information. Health Economicsand Drugs, EDM Series No.3. Geneva, World Health Organization, 2000 (EDM/PAR/2000.2).22http://www3.who.int/whosis/cmh/cmh_report/e/pdf/001-004.pdf23World medicines situation. Geneva, World Health Organization (In preparation).24Health reform and drug financing. Geneva, World Health Organization, 1998 (WHO/DAP/98.3).25World health report 1999: Making a difference. Geneva World Health Organization; 1999; Worldhealth report 2000; Shaping the future. Geneva World Health Organization, 2000; Public-private rolesin the pharmaceutical sector. Geneva, World Health Organization, 1997 (WHO/DAP/97.12).26Global Fund to Fight Aids, Tuberculosis and Malaria (http://www.globalfundatm.org).27World Bank HIV/AIDS (http://www1.worldbank.org/hiv_aids/index.asp).28World health report 1999: Making a difference. Geneva, World Health Organization, 1999.29What is WHO doing to improve drug price information? WHO Fact Sheet: Drug Price InformationServices. (http://www.who.int/medicines/organization/par/ipc/drugpriceinfo.shtml).30Medicine prices: a new approach to measurement. Geneva, World Health Organization and HealthAction International, 2003 (WHO/EDM/PAR/2003.2).31The use of essential drugs Report of the WHO Expert Committee 1997 (including the 10 th Model List